Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

José C. Armario-Hita

Professor of Dermatology

Universidad de Cádiz

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

20%

Pharmacotherapy

90%

Dermatology

80%

Immunotherapy

50%

Anti-inflammatory Research

40%

Psoriasis

40%

Atopic Dermatitis

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles15

Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi‐Criteria Decision Analysis

Article Link

Year:

2024

Response to “Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’”

Article Link

Year:

2024

Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain

Article Link

Year:

2024

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

Article Link

Year:

2024

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

Article Link

Year:

2024

Mechanism, Diagnostic and Therapeutic Novelties in Dermatology: Where Are We Going?

Article Link

Year:

2024

Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA)

Article Link

Year:

2023

Upadacitinib for moderate to severe atopic dermatitis

Article Link

Year:

2023

Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis

Article Link

Year:

2022

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives

Article Link

Year:

2022

Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)

Article Link

Year:

2022

Unveiling the true costs and societal impacts of moderate‐to‐severe atopic dermatitis in Europe

Article Link

Year:

2022

104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain

Article Link

Year:

2021

Drug survival of systemic and biological treatments for moderate‐to‐severe atopic dermatitis in adults: a multicentre retrospective observational study

Article Link

Year:

2021

Efficiency in patch testing: the number needed to test to get one relevant result as a new approach in the evaluation of baseline series

Article Link

Year:

2020

Collaborators4

Ricardo Ruiz-Villaverde

SPAIN

José Manuel Dodero Anillo

Sanitary Vinculated Proffesor

Universidad de Cádiz

SPAIN

Jose-Juan Pereyra-Rodriguez

SPAIN

jose-manuel carrascosa

head of department, associated professor

Hospital Universitari Germans Trias i Pujol

SPAIN

How do I reach out?

Meet Kite AI